RGB 286638

Drug Profile

RGB 286638

Alternative Names: RGB-286638

Latest Information Update: 13 Oct 2011

Price : $50

At a glance

  • Originator GPC Biotech AG
  • Developer Agennix AG
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 12 Oct 2011 RGB 286638 is still in a phase I trial for Solid tumours in Netherlands
  • 16 Nov 2010 Interim adverse events data, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR)
  • 21 Apr 2009 Preclinical pharmacodynamics data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top